newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib

  • The FDA granted Breakthrough Therapy Designation for bezuclastinib in patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) previously treated with avapritinib.
  • The FDA also granted Breakthrough Therapy Designation for bezuclastinib in patients with Smoldering Systemic Mastocytosis.
  • Both designated populations currently have no approved standard of care.
  • Cogent Biosciences plans to submit a New Drug Application (NDA) for NonAdvSM by the end of 2025 following a productive pre-NDA meeting.
  • The Breakthrough Therapy Designation is based on positive results from the SUMMIT trial, where bezuclastinib achieved statistical significance across all primary & key secondary endpoints.
  • Detailed results from the SUMMIT trial are planned for presentation at an upcoming scientific conference later in 2025.
  • The designation supports eligibility for Priority Review & rolling submission of the application.
  • Cogent plans to report top-line results from the Phase 3 PEAK trial in Gastrointestinal Stromal Tumors (GIST) in November 2025.
  • Cogent plans to report top-line results from the registration-directed APEX trial in Advanced Systemic Mastocytosis (AdvSM) in December 2025.
  • Bezuclastinib is a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation & other mutations in KIT exon 17.